family with sequence similarity 185 member AGenealiases: []
Q-omics provides the consensus-scored FAM185A profile across patient tissues and cancer cell-line models. FAM185A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, FAM185A is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, FAM185A RNA expression shows 20,474 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, and ACC as cancer lineages where FAM185A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM185A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM185A survival associations across molecular data types. FAM185A RNA expression shows survival associations in the most cancer types (23), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM185A RNA expression–survival associations across cancer types. High FAM185A expression shows unfavorable associations in KICH, ACC and COAD, but favorable associations in KIRC, OV and READ. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for FAM185A RNA expression.
This table summarizes FAM185A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM185A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM185A shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, LUAD, CHOL and HNSC. The KICH box plot shows higher FAM185A RNA expression in normal versus tumor tissue (log2 FC = −0.899, t-test p < 0.001).
This table shows molecular features associated with FAM185A in patient tissues and cancer cell lines. In patient samples, FAM185A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM185A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and UPPER_AERODIGESTIVE_TRACT.
